← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $169B	2,059	+95	+5%	$140B
2	2 Amgen AMGN $238B	1,541	+23	+2%	$84.9B
3	3 Eli Lilly LLY $1.13T	1,212	+35	+3%	$61.1B
4	4 Becton Dickinson BDX $52.4B	1,033	+49	+5%	$29.4B
5	5 McKesson MCK $116B	889	-52	-6%	$25.9B
6	6 Teva Pharmaceutical Industries Limited TEVA $48.2B	739	-59	-7%	$21.9B
7	7 Conagra Brands CAG $6.84B	696	+2	+0.3%	$13.4B
8	8 Regeneron Pharmaceuticals REGN $82.9B	576	+21	+4%	$26.3B
9	9 Novo Nordisk NVO $174B	483	-30	-6%	$5.59B
10	10 DaVita DVA $11.9B	479	-3	-0.6%	$10.7B
11	11 AstraZeneca AZN $260B	450	-1	-0.2%	$8.63B
12	12 Lamb Weston LW $7.46B	449	+449	–	$4.29B
13	13 ResMed RMD $33.8B	362	-13	-3%	$5.47B
14	14 West Pharmaceutical WST $26.9B	288	+8	+3%	$5.69B
15	15 Accendra Health ACH $22M	285	-1	-0.3%	$2.06B
16	16 Opko Health OPK $1.19B	256	-14	-5%	$1.24B
17	17 Herbalife HLF $1.52B	210	-22	-9%	$4.82B
18	18 DELISTED CATALENT, INC. CTLT	206	+4	+2%	$3.45B
19	19 Fresenius Medical Care FMS $11.8B	185	+3	+2%	$665M
20	20 Tootsie Roll Industries TR $2.92B	182	+6	+3%	$546M
21	21 MannKind Corp MNKD $1.01B	165	+14	+9%	$59M
22	22 Dr. Reddy's Laboratories RDY $10.8B	164	+7	+4%	$1.24B
23	23 Medifast MED $136M	162	-3	-2%	$438M
24	24 Lexicon Pharmaceuticals LXRX $725M	146	+2	+1%	$1.53B
25	25 Amphastar Pharmaceuticals AMPH $1.14B	138	+3	+2%	$412M